Modifications by Chronic Intermittent Hypoxia and Drug Treatment on Skeletal Muscle Metabolism
Overview
Affiliations
The energy metabolism was evaluated in gastrocnemius muscle from 3-month-old rats subjected to either mild or severe 4-week intermittent normobaric hypoxia. Furthermore, 4-week treatment with CNS-acting drugs, namely, alpha-adrenergic (delta-yohimbine), vasodilator (papaverine, pinacidil), or oxygen-increasing (almitrine) agents was performed. The muscular concentration of the following metabolites was evaluated: glycogen, glucose, glucose 6-phosphate, pyruvate, lactate, lactate-to-pyruvate ratio; citrate, alpha-ketoglutarate, succinate, malate; aspartate, glutamate, alanine; ammonia; ATP, ADP, AMP, creatine phosphate. Furthermore the Vmax of the following muscular enzymes was evaluated: hexokinase, phosphofructokinase, pyruvate kinase, lactate dehydrogenase; citrate synthase, malate dehydrogenase; total NADH cytochrome c reductase; cytochrome oxidase. The adaptation to chronic intermittent normobaric mild or severe hypoxia induced alterations of the components in the anaerobic glycolytic pathway [as supported by the increased activity of lactate dehydrogenase and/or hexokinase, resulting in the decreased glycolytic substrate concentration consistent with the increased lactate production and lactate-to-pyruvate ratio] and in the mitochondrial mechanism [as supported by the decreased activity of malate dehydrogenase and/or citrate synthase resulting in the decreased concentration of some key components in the tricarboxylic acid cycle]. The effect of the concomitant pharmacological treatment suggests that the action of CNS-acting drugs could be also related to their direct influence on the muscular biochemical mechanisms linked to energy transduction.
Hypometabolic Responses to Chronic Hypoxia: A Potential Role for Membrane Lipids.
Farhat E, Weber J Metabolites. 2021; 11(8).
PMID: 34436444 PMC: 8399526. DOI: 10.3390/metabo11080503.
Naked mole-rats suppress energy metabolism and modulate membrane cholesterol in chronic hypoxia.
Farhat E, Devereaux M, Pamenter M, Weber J Am J Physiol Regul Integr Comp Physiol. 2020; 319(2):R148-R155.
PMID: 32663032 PMC: 7473896. DOI: 10.1152/ajpregu.00057.2020.
Chien M, Lee P, Yu C, Wei S, Shih T Nat Sci Sleep. 2020; 12:69-78.
PMID: 32095087 PMC: 6995288. DOI: 10.2147/NSS.S232554.
Gea J, Sancho-Munoz A, Chalela R J Thorac Dis. 2018; 10(Suppl 12):S1332-S1354.
PMID: 29928517 PMC: 5989104. DOI: 10.21037/jtd.2018.02.66.
Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E J Thorac Dis. 2015; 7(10):E418-38.
PMID: 26623119 PMC: 4635259. DOI: 10.3978/j.issn.2072-1439.2015.08.04.